Trademark Overview
On Monday, March 16, 2026, a trademark application was filed for ZEYDOVIO with the United States Patent and Trademark Office. The USPTO has given the ZEYDOVIO trademark a serial number of 79450596. The federal status of this trademark filing is NON-FINAL ACTION COUNTED - NOT MAILED as of Thursday, June 25, 2026. This trademark is owned by ZEALAND PHARMA A/S. The ZEYDOVIO trademark is filed in the Pharmaceutical Products, Medical Instrument Products, and Medical & Beauty Services & Agricultural Services categories with the following description:
Medical and pharmaceutical services, namely in relation to treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS); medical and pharmaceutical advice, namely in relation to treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS); medical and pharmaceutical services, namely in relation to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.
Devices for introducing pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS), and parts and fittings therefor; devices for introducing pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia, and parts and fittings therefor.
Pharmaceutical preparations, namely for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS); medical preparations, namely for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS); pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.